Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 25,488	$ 32,042	$ 77,885	$ 86,302
Cost of revenues	958	1,184	2,707	3,386
Gross profit	24,530	30,858	75,178	82,916
Operating expenses excluding cost of revenues:
Selling and marketing	13,699	13,928	40,655	44,695
Research and development	2,775	3,009	8,312	9,212
General and administrative	3,823	1,157	10,645	4,607
Total operating expenses excluding cost of revenues	20,297	18,094	59,612	58,514
Income from operations	4,233	12,764	15,566	24,402
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	237		264
Total assets	125,240		125,240		$ 116,539
Purchase of property and equipment			2,380	6,193
General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	237		264
Gyre Pharmaceuticals
Segment Reporting Information [Line Items]
Revenues	25,488	32,042	77,885	86,302
Cost of revenues	958	1,184	2,707	3,386
Gross profit	24,530	30,858	75,178	82,916
Operating expenses excluding cost of revenues:
Selling and marketing	13,699	13,928	40,655	44,695
Research and development	2,553	3,009	7,639	9,212
General and administrative	2,225	1,159	7,031	4,055
Total operating expenses excluding cost of revenues	18,477	18,096	55,325	57,962
Income from operations	6,053	12,762	19,853	24,954
Supplemental disclosure of stock-based compensation expense:
Total assets	113,682		113,682		101,761
Purchase of property and equipment			2,366	6,193
Gyre
Operating expenses excluding cost of revenues:
Research and development	222		673
General and administrative	1,593		3,608
Total operating expenses excluding cost of revenues	1,815		4,281
Income from operations	(1,815)		(4,281)
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	237		264
Total assets	10,646		10,646		13,865
Purchase of property and equipment			14
Gyre | General and administrative
Supplemental disclosure of stock-based compensation expense:
Stock-based compensation	237		264
Other
Operating expenses excluding cost of revenues:
General and administrative	5	(2)	6	552
Total operating expenses excluding cost of revenues	5	(2)	6	552
Income from operations	(5)	$ 2	(6)	$ (552)
Supplemental disclosure of stock-based compensation expense:
Total assets	$ 912		$ 912		$ 913